PTCT Earnings Ptc Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–46 of 46
| Q3 2026 | 2026-09-30 | -0.62 | 2026-10-29 | 10-Q |
| Q2 2026 | 2026-06-30 | 0.92 | 2026-07-30 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.03 | 2026-05-07 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -1.63 | 2026-02-19 | 10-K |
| FY 2025 | 2025-12-31 | 7.78 | 2026-02-19 | 10-K |
| Q3 2025 | 2025-09-30 | 0.20 | 2025-11-04 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.83 | 2025-08-07 | 10-Q |
| Q1 2025 | 2025-03-31 | 10.04 | 2025-05-06 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -0.85 | 2025-02-27 | 10-K |
| FY 2024 | 2024-12-31 | -4.73 | 2025-02-27 | 10-K |
| Q3 2024 | 2024-09-30 | -1.39 | 2024-11-07 | 10-Q |
| Q2 2024 | 2024-06-30 | -1.29 | 2024-08-08 | 10-Q |
| Q1 2024 | 2024-03-31 | -1.20 | 2024-04-25 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -2.07 | 2024-02-29 | 10-K |
| FY 2023 | 2023-12-31 | -8.37 | 2024-02-29 | 10-K |
| Q3 2023 | 2023-09-30 | -1.76 | 2023-10-26 | 10-Q |
| Q2 2023 | 2023-06-30 | -2.66 | 2023-08-03 | 10-Q |
| Q1 2023 | 2023-03-31 | -1.88 | 2023-04-27 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -2.35 | 2023-02-21 | 10-K |
| FY 2022 | 2022-12-31 | -7.79 | 2023-02-21 | 10-K |
| Q3 2022 | 2022-09-30 | -1.53 | 2022-10-27 | 10-Q |
| Q2 2022 | 2022-06-30 | -2.13 | 2022-08-04 | 10-Q |
| Q1 2022 | 2022-03-31 | -1.78 | 2022-05-03 | 10-Q |
| Q4 2021 (derived) | 2021-12-31 | -2.03 | 2022-02-22 | 10-K |
| FY 2021 | 2021-12-31 | -7.43 | 2022-02-22 | 10-K |
| Q3 2021 | 2021-09-30 | -1.89 | — | — |
| Q2 2021 | 2021-06-30 | -1.68 | — | — |
| Q1 2021 | 2021-03-31 | -1.83 | — | — |
| FY 2020 | 2020-12-31 | -6.64 | — | — |
| FY 2019 | 2019-12-31 | -4.27 | — | — |
| Q4 2014 | 2014-12-31 | -0.84 | 2015-03-02 | 10-K |
| FY 2014 | 2014-12-31 | -2.97 | 2015-03-02 | 10-K |
| Q3 2014 | 2014-09-30 | -0.93 | — | — |
| Q2 2014 | 2014-06-30 | -0.86 | — | — |
| Q1 2014 | 2014-03-31 | -0.58 | — | — |
| Q4 2013 | 2013-12-31 | -0.75 | 2014-03-06 | 10-K |
| FY 2013 | 2013-12-31 | -5.18 | 2014-03-06 | 10-K |
| Q3 2013 | 2013-09-30 | -0.19 | 2013-11-14 | 10-Q |
| Q2 2013 | 2013-06-30 | -5.51 | 2013-08-13 | 10-Q |
| Q1 2013 | 2013-03-31 | -6527.30 | — | — |
| Q4 2012 | 2012-12-31 | -1380.13 | — | — |
| FY 2012 | 2012-12-31 | 42.50 | — | — |
| Q3 2012 | 2012-09-30 | -1605.53 | — | — |
| Q2 2012 | 2012-06-30 | 48.29 | — | — |
| Q1 2012 | 2012-03-31 | -5992.61 | — | — |
| FY 2011 | 2011-12-31 | 4.55 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.